Intellia Therapeutics Inc (NTLA) Receives $41.90 Average Price Target from Analysts

Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) have received a consensus recommendation of “Hold” from the fourteen analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $41.90.

A number of research firms have commented on NTLA. Zacks Investment Research raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research report on Saturday, August 4th. BidaskClub raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, September 28th. Chardan Capital reaffirmed a “buy” rating and issued a $57.50 target price on shares of Intellia Therapeutics in a research report on Friday, August 24th. ValuEngine cut shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, September 22nd. Finally, Raymond James started coverage on shares of Intellia Therapeutics in a research report on Thursday, September 20th. They issued a “market perform” rating on the stock.

Several institutional investors and hedge funds have recently modified their holdings of NTLA. Nisa Investment Advisors LLC increased its stake in shares of Intellia Therapeutics by 113.8% during the third quarter. Nisa Investment Advisors LLC now owns 17,100 shares of the company’s stock worth $489,000 after buying an additional 9,100 shares during the period. Nikko Asset Management Americas Inc. purchased a new stake in shares of Intellia Therapeutics during the third quarter worth approximately $141,000. Elmwood Wealth Management Inc. increased its stake in shares of Intellia Therapeutics by 8.3% during the third quarter. Elmwood Wealth Management Inc. now owns 65,327 shares of the company’s stock worth $1,870,000 after buying an additional 4,985 shares during the period. Northern Trust Corp increased its stake in shares of Intellia Therapeutics by 97.3% during the second quarter. Northern Trust Corp now owns 364,171 shares of the company’s stock worth $9,963,000 after buying an additional 179,553 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Intellia Therapeutics by 55.4% during the second quarter. Bank of New York Mellon Corp now owns 123,494 shares of the company’s stock worth $3,379,000 after buying an additional 44,015 shares during the period. 66.50% of the stock is currently owned by institutional investors and hedge funds.

Shares of NTLA stock traded down $0.58 on Friday, hitting $23.95. 3,622 shares of the stock traded hands, compared to its average volume of 903,570. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -12.97 and a beta of 3.14. Intellia Therapeutics has a twelve month low of $16.33 and a twelve month high of $35.99.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Wednesday, August 1st. The company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.03. Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The company had revenue of $7.68 million for the quarter, compared to analysts’ expectations of $6.39 million. During the same quarter in the prior year, the company posted ($0.45) earnings per share. Intellia Therapeutics’s revenue for the quarter was up 30.2% compared to the same quarter last year. On average, analysts expect that Intellia Therapeutics will post -1.97 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Featured Story: What is a Stop Order?

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply